NEW YORK – Precision oncology firm Burning Rock Biotech this week presented data at two scientific conferences supporting two products it expects to be major growth drivers in coming years.
At the annual meeting of the Association for Molecular Pathology, held virtually, researchers from the company presented a study describing the validation of its automated next-generation sequencing library prep solution Magnis BR, which was launched last year.